Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials

Roy F. Chemaly, Sunwen Chou, Hermann Einsele, Paul Griffiths, Robin Avery, Raymund R. Razonable, Kathleen M. Mullane, Camille Kotton, Jens Lundgren, Takashi E. Komatsu, Peter Lischka, Filip Josephson, Cameron M. Douglas, Obi Umeh, Veronica Miller, Per Ljungman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major complication in solid organ and hematopoietic cell transplant recipients. CMV infection may fail to respond to commercially available antiviral therapies, with or without demonstrating genotypic mutation(s) known to be associated with resistance to these therapies. This lack of response has been termed "resistant/refractory CMV" and is a key focus of clinical trials of some investigational antiviral agents. To provide consistent criteria for future clinical trials and outcomes research, the CMV Resistance Working Group of the CMV Drug Development Forum (consisting of scientists, clinicians, regulatory officials, and industry representatives from the United States, Canada, and Europe) has undertaken establishing standardized consensus definitions of "resistant" and "refractory" CMV. These definitions have emerged from the Working Group's review of the available virologic and clinical literature and will be subject to reassessment and modification based on results of future studies.

Original languageEnglish (US)
Pages (from-to)1420-1426
Number of pages7
JournalClinical Infectious Diseases
Volume68
Issue number8
DOIs
StatePublished - Apr 8 2019

Fingerprint

Cytomegalovirus Infections
Cytomegalovirus
Clinical Trials
Antiviral Agents
Canada
Industry
Outcome Assessment (Health Care)
Transplants
Mutation
Transplant Recipients
Therapeutics
Pharmaceutical Preparations

Keywords

  • clinical trials
  • cytomegalovirus
  • definitions
  • refractory
  • resistance

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. / Chemaly, Roy F.; Chou, Sunwen; Einsele, Hermann; Griffiths, Paul; Avery, Robin; Razonable, Raymund R.; Mullane, Kathleen M.; Kotton, Camille; Lundgren, Jens; Komatsu, Takashi E.; Lischka, Peter; Josephson, Filip; Douglas, Cameron M.; Umeh, Obi; Miller, Veronica; Ljungman, Per.

In: Clinical Infectious Diseases, Vol. 68, No. 8, 08.04.2019, p. 1420-1426.

Research output: Contribution to journalArticle

Chemaly, RF, Chou, S, Einsele, H, Griffiths, P, Avery, R, Razonable, RR, Mullane, KM, Kotton, C, Lundgren, J, Komatsu, TE, Lischka, P, Josephson, F, Douglas, CM, Umeh, O, Miller, V & Ljungman, P 2019, 'Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials', Clinical Infectious Diseases, vol. 68, no. 8, pp. 1420-1426. https://doi.org/10.1093/cid/ciy696
Chemaly, Roy F. ; Chou, Sunwen ; Einsele, Hermann ; Griffiths, Paul ; Avery, Robin ; Razonable, Raymund R. ; Mullane, Kathleen M. ; Kotton, Camille ; Lundgren, Jens ; Komatsu, Takashi E. ; Lischka, Peter ; Josephson, Filip ; Douglas, Cameron M. ; Umeh, Obi ; Miller, Veronica ; Ljungman, Per. / Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. In: Clinical Infectious Diseases. 2019 ; Vol. 68, No. 8. pp. 1420-1426.
@article{6bdb23efe47f4da9ab2e8321a2fdc992,
title = "Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials",
abstract = "Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major complication in solid organ and hematopoietic cell transplant recipients. CMV infection may fail to respond to commercially available antiviral therapies, with or without demonstrating genotypic mutation(s) known to be associated with resistance to these therapies. This lack of response has been termed {"}resistant/refractory CMV{"} and is a key focus of clinical trials of some investigational antiviral agents. To provide consistent criteria for future clinical trials and outcomes research, the CMV Resistance Working Group of the CMV Drug Development Forum (consisting of scientists, clinicians, regulatory officials, and industry representatives from the United States, Canada, and Europe) has undertaken establishing standardized consensus definitions of {"}resistant{"} and {"}refractory{"} CMV. These definitions have emerged from the Working Group's review of the available virologic and clinical literature and will be subject to reassessment and modification based on results of future studies.",
keywords = "clinical trials, cytomegalovirus, definitions, refractory, resistance",
author = "Chemaly, {Roy F.} and Sunwen Chou and Hermann Einsele and Paul Griffiths and Robin Avery and Razonable, {Raymund R.} and Mullane, {Kathleen M.} and Camille Kotton and Jens Lundgren and Komatsu, {Takashi E.} and Peter Lischka and Filip Josephson and Douglas, {Cameron M.} and Obi Umeh and Veronica Miller and Per Ljungman",
year = "2019",
month = "4",
day = "8",
doi = "10.1093/cid/ciy696",
language = "English (US)",
volume = "68",
pages = "1420--1426",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials

AU - Chemaly, Roy F.

AU - Chou, Sunwen

AU - Einsele, Hermann

AU - Griffiths, Paul

AU - Avery, Robin

AU - Razonable, Raymund R.

AU - Mullane, Kathleen M.

AU - Kotton, Camille

AU - Lundgren, Jens

AU - Komatsu, Takashi E.

AU - Lischka, Peter

AU - Josephson, Filip

AU - Douglas, Cameron M.

AU - Umeh, Obi

AU - Miller, Veronica

AU - Ljungman, Per

PY - 2019/4/8

Y1 - 2019/4/8

N2 - Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major complication in solid organ and hematopoietic cell transplant recipients. CMV infection may fail to respond to commercially available antiviral therapies, with or without demonstrating genotypic mutation(s) known to be associated with resistance to these therapies. This lack of response has been termed "resistant/refractory CMV" and is a key focus of clinical trials of some investigational antiviral agents. To provide consistent criteria for future clinical trials and outcomes research, the CMV Resistance Working Group of the CMV Drug Development Forum (consisting of scientists, clinicians, regulatory officials, and industry representatives from the United States, Canada, and Europe) has undertaken establishing standardized consensus definitions of "resistant" and "refractory" CMV. These definitions have emerged from the Working Group's review of the available virologic and clinical literature and will be subject to reassessment and modification based on results of future studies.

AB - Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major complication in solid organ and hematopoietic cell transplant recipients. CMV infection may fail to respond to commercially available antiviral therapies, with or without demonstrating genotypic mutation(s) known to be associated with resistance to these therapies. This lack of response has been termed "resistant/refractory CMV" and is a key focus of clinical trials of some investigational antiviral agents. To provide consistent criteria for future clinical trials and outcomes research, the CMV Resistance Working Group of the CMV Drug Development Forum (consisting of scientists, clinicians, regulatory officials, and industry representatives from the United States, Canada, and Europe) has undertaken establishing standardized consensus definitions of "resistant" and "refractory" CMV. These definitions have emerged from the Working Group's review of the available virologic and clinical literature and will be subject to reassessment and modification based on results of future studies.

KW - clinical trials

KW - cytomegalovirus

KW - definitions

KW - refractory

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=85064117112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064117112&partnerID=8YFLogxK

U2 - 10.1093/cid/ciy696

DO - 10.1093/cid/ciy696

M3 - Article

VL - 68

SP - 1420

EP - 1426

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 8

ER -